Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

37,413 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Neoadjuvant docetaxel plus carboplatin vs epirubicin plus cyclophosphamide followed by docetaxel in triple-negative, early-stage breast cancer (NeoCART): Results from a multicenter, randomized controlled, open-label phase II trial.
Zhang L, Wu ZY, Li J, Lin Y, Liu Z, Cao Y, Zhang G, Gao HF, Yang M, Yang CQ, Zhu T, Cheng MY, Ji F, Li J, Wang K. Zhang L, et al. Among authors: wang k. Int J Cancer. 2022 Feb 15;150(4):654-662. doi: 10.1002/ijc.33830. Epub 2021 Oct 7. Int J Cancer. 2022. PMID: 34591977 Free article. Clinical Trial.
A Novel Predictive Nomogram including Serum Lipoprotein a Level for Nonsentinel Lymph Node Metastases in Chinese Breast Cancer Patients with Positive Sentinel Lymph Node Metastases.
Fang Z, Wang R, Yang C, Wang D, Chen W, Lin B, Gong D, Li S, Liang J, Liang X, Zeng C, Li J, Wang K, Lv W. Fang Z, et al. Among authors: wang k, wang d, wang r. Dis Markers. 2021 Nov 22;2021:7879508. doi: 10.1155/2021/7879508. eCollection 2021. Dis Markers. 2021. PMID: 34853623 Free PMC article.
Impact of Homologous Recombination Deficiency on Outcomes in Patients With Triple-Negative Breast Cancer Treated With Carboplatin-Based Neoadjuvant Chemotherapy: Secondary Analysis of the NeoCART Randomized Clinical Trial.
Zhang L, Wu Z, Li J, Zhu D, Yang L, Shao Y, Lin Y, Liu Z, Cao Y, Zhang G, Shang S, Zhang Y, Wang K. Zhang L, et al. Among authors: wang k. JCO Precis Oncol. 2023 Jan;7:e2200337. doi: 10.1200/PO.22.00337. JCO Precis Oncol. 2023. PMID: 36652665 Clinical Trial.
37,413 results
You have reached the last available page of results. Please see the User Guide for more information.